{"nctId":"NCT02338193","briefTitle":"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women","startDateStruct":{"date":"2015-09-22","type":"ACTUAL"},"conditions":["Diabetes Prevention in Women After GDM Who Are at High-risk"],"count":69,"armGroups":[{"label":"DAPA/MET Extended Release (XR)","type":"EXPERIMENTAL","interventionNames":["Drug: DAPA/MET XR"]},{"label":"Dapaglifloxin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DAPA"]},{"label":"Metformin XR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: MET XR"]}],"interventions":[{"name":"DAPA/MET XR","otherNames":["Xigduo 5mg/1000 mg"]},{"name":"DAPA","otherNames":["Farxiga 10 mg"]},{"name":"MET XR","otherNames":["Glucophage XR 500 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* • Overweight/obese (BMI \\>25) females 18 years to 45 years of age, who experienced gestational diabetes (GDM) during recent (within 12 months) pregnancy\n\n  * postpartum metabolic abnormalities determined by a 75 g oral glucose tolerance test (Inclusive of prior GDM women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) postpartum)\n  * Completed lactation\n  * Using adequate contraception during study period unless sterilized\n  * Written consent for participation in the study\n\nExclusion Criteria:\n\n* Cholestasis during the past pregnancy\n* Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology), gallstones, abnormal liver function tests or renal impairment (elevated serum creatinine levels or abnormal creatinine clearance\n* Presence of significant systemic disease, heart problems including congestive heart failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)\n* Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR \\<60)\n* Significantly elevated triglyceride levels (fasting triglyceride \\> 400 mg %)\n* Untreated or poorly controlled hypertension (sitting blood pressure \\>160/95mm Hg)\n* Prior history of a malignant disease requiring chemotherapy\n* Known hypersensitivity or contraindications to use of insulin sensitizers such as metformin or thiazolidinediones\n* History of hypersensitivity reaction to dapagliflozin or other SGLT2 inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions)\n* Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors or weight loss medications (prescription or OTC)\n* Uncontrolled thyroid disease (documented normal TSH) or hyperprolactinemia\n* Liver enzymes (serum alanine aminotransferase \\[ALT\\] and/or aspartate aminotransferase \\[AST\\] ) levels exceeding more than twice normal lab values\n* Use of drugs known to exacerbate glucose tolerance\n* History of diabetes or prior use of medications to treat diabetes except GDM\n* Currently lactating\n* Eating disorders (anorexia, bulimia) or gastrointestinal disorders\n* Suspected pregnancy (documented negative serum pregnancy test within 72 hours before first dose of study drug), desiring pregnancy in next 6 months, breastfeeding, or known pregnancy in last 2 months\n* Active or prior history of substance abuse (smoke or tobacco use within past 3 years) or significant intake of alcohol or history of alcoholism\n* Patient not willing to use adequate contraception during study period and up to 4 weeks after last dose of study drug (unless sterilized).\n* Debilitating psychiatric disorder such as psychosis or neurological condition that might confound outcome variables\n* Inability or refusal to comply with protocol\n* Not currently participating or having participated in an experimental drug study in previous three months","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight","description":"Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.5","spread":"14"},{"groupId":"OG001","value":"-12.5","spread":"20"},{"groupId":"OG002","value":"-4.4","spread":"18"}]}]}]},{"type":"SECONDARY","title":"Change in Percent Body Weight","description":"Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"3.1"},{"groupId":"OG001","value":"-3.2","spread":"4.5"},{"groupId":"OG002","value":"-1.1","spread":"4.4"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index (BMI)","description":"BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":"6.2"},{"groupId":"OG001","value":"33.7","spread":"7.7"},{"groupId":"OG002","value":"31","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Waist Circumference (WC)","description":"Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":"12.7"},{"groupId":"OG001","value":"95","spread":"16.6"},{"groupId":"OG002","value":"91.7","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)","description":"Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.055"},{"groupId":"OG001","value":"0.80","spread":".06"},{"groupId":"OG002","value":"0.83","spread":".06"}]}]}]},{"type":"SECONDARY","title":"Waist-to-height Ratio (WHtR)","description":"Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":".06"},{"groupId":"OG001","value":"0.57","spread":".09"},{"groupId":"OG002","value":"0.56","spread":".06"}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure (DBP)","description":"Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":"11"},{"groupId":"OG001","value":"77.8","spread":"11"},{"groupId":"OG002","value":"79","spread":"7.5"}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure (SBP)","description":"Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":"12"},{"groupId":"OG001","value":"124","spread":"13"},{"groupId":"OG002","value":"119.6","spread":"10.4"}]}]}]},{"type":"SECONDARY","title":"Liver Enzymes","description":"ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":".35"},{"groupId":"OG001","value":"1.12","spread":".32"},{"groupId":"OG002","value":"1.18","spread":".3"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol Levels (CHOL)","description":"Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":"45"},{"groupId":"OG001","value":"168","spread":"32"},{"groupId":"OG002","value":"178","spread":"31"}]}]}]},{"type":"SECONDARY","title":"Triglyceride (TRG) Levels","description":"Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":"59"},{"groupId":"OG001","value":"89.8","spread":"39"},{"groupId":"OG002","value":"212","spread":"64"}]}]}]},{"type":"SECONDARY","title":"Fasting Blood Glucose (FBG)","description":"Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":"7.9"},{"groupId":"OG001","value":"91","spread":"9.2"},{"groupId":"OG002","value":"87","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Mean Blood Glucose (MBG) During an OGTT","description":"Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.5","spread":"15.2"},{"groupId":"OG001","value":"110.1","spread":"17.8"},{"groupId":"OG002","value":"112.5","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Fasting Insulin Sensitivity (HOMA-IR)","description":"HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.6"},{"groupId":"OG001","value":"2.4","spread":"1.4"},{"groupId":"OG002","value":"1.8","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Matsuda Sensitivity Index (SI OGTT)","description":"Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"3.2"},{"groupId":"OG001","value":"6.3","spread":"4.4"},{"groupId":"OG002","value":"5.42","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"First Phase Insulin Secretion (IGI/HOMA-IR)","description":"Corrected early insulin response to glucose challenge \\[(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)\\] with combination therapy compared to monotherapy after 24 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"3.2"},{"groupId":"OG001","value":"1.1","spread":"1.2"},{"groupId":"OG002","value":"0.77","spread":".53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Yeast infection","Nausea/diarrhea"]}}}